[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634856":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":57,"collaborators":24,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":21,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":24,"enrollmentInfo":68,"targetDuration":24,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":24,"overallStatus":34,"whyStopped":24,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Context Therapeutics Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1a","EXPERIMENTAL","Dose Escalation-Bayesian Optimal Interval (BOIN) Design with approximately 54 patients in dose escalation.",[13],"Drug: CT-202",{"label":15,"type":10,"description":16,"interventionNames":17},"Phase 1b","Phase 1b: Dose Expansion - participants will be evaluated in 4-6 cohorts at different doses and schedules of CT-202",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","CT-202","Nectin-4 bispecific",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Context Clinical Development","CONTACT","267.225.7416","Cntx-ct202-101@contexttherapeutics.com",[32,45,48],{"facility":33,"status":34,"city":35,"state":36,"zip":24,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":24},"Tasman Oncology Research","RECRUITING","Gold Coast","Queensland","Australia","AU",{"type":40,"coordinates":41},"Point",[42,43],153.43088,-28.00029,{"lat":43,"lon":42},{"facility":46,"status":34,"city":47,"state":36,"zip":24,"country":37,"countryCode":38,"cosmosGeoPoint":24,"geoPoint":24,"contacts":24},"Calvary Mater Hospital Newcastle","Newcastle",{"facility":49,"status":34,"city":50,"state":51,"zip":24,"country":37,"countryCode":38,"cosmosGeoPoint":52,"geoPoint":56,"contacts":24},"Linear Clinical Research","Perth","Western Australia",{"type":40,"coordinates":53},[54,55],115.8614,-31.95224,{"lat":55,"lon":54},{"type":58,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100634856","phase-1-a-phase-1a1b-first-time-in-human-study-of-ct-202-a-nectin-4-directed-bispecific-antibody-in-participants-with-recurring-triple-negative-breast-colorectal-urothelial-cancers-100634856",false,"NCT07545122","A Phase 1a\u002F1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers","A Phase 1a\u002F1b, First Time in Human Study of CT-202, A Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, and Urothelial Cancers","Inclusion Criteria:\n\n* Participants with nectin-4-positive triple negative breast cancer, colorectal cancer, or urothelial cancer that have received standard therapies\n* Participants with measurable disease per RECIST 1.1\n* ECOG 0, 1, or 2 and life expectancy of ≥ 12 weeks\n* Participants have adequate organ function.\n\nExclusion Criteria:\n\n* History of severe skin toxicity\n* Uncontrolled significant active infection or any medical or other condition that in the opinion of the Investigator would preclude the participant's participation in the study.\n* Concurrent participation in another investigational clinical trial.","ALL","18 Years",{"count":69,"type":70},162,"ESTIMATED","INTERVENTIONAL",[73],"PHASE1","This is a Phase 1a\u002F1b, first time in human (FTIH), open-label, dose escalation and expansion study to evaluate the safety, tolerability, and preliminary efficacy of CT-202 (study drug), a humanized T cell engaging bispecific antibody targeting nectin-4, in participants with nectin-4 expressing recurrent, unresectable or metastatic refractory\u002Fresistant TNBC, CRC, or UC. Results of the study including PK, PD, efficacy, and safety will be used in the RP2D determination.",[76,77,78],"Triple Negative Breast Cancer (TNBC)","Colorectal Cancer","Urothelial Cancer","2026-08-14",{"date":81,"type":82},"2026-08-18","ACTUAL",{"date":84,"type":70},"2026-09",{"date":86,"type":70},"2030-01",{"name":5,"class":6},3]